INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus

Pfizer

Status: Completed

Conditions: Carcinoma, Renal Cell; Lymphoma, Mantle-Cell

Treatments: Other: Temsirolimus (Non-Interventional Study)

Study type: Observational

Funder types: Industry

Identifiers

NCT01367457

INHIBITOR (Other Identifier)

B1771017

Details and patient eligibility

About

The principal objective of the study is to evaluate the efficacy and safety of temsirolimus use in patients with Renal Cell Carcinoma and Mantle Cell Lymphoma.

Full description

There is not sampling method

Enrollment: 243 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.

Exclusion criteria

Patients that do not have a minimum (pre-specified) of data in their clinical record.

Trial design

243 participants in 1 patient group

Patients that received treatment with Temsirolimus

Description:

Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.

Treatment:

Other: Temsirolimus (Non-Interventional Study)